

F. No. 31026/24/2017-Pricing
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
(Pricing Section)

Room No. 235, A-Wing, Shastri Bhawan,
New Delhi dated, the 05.03.2018

To

M/s Fulfords (India) Limited
8th & 10th Floor, Plot No. C 59
G Block, platina Building,
Bandra East, Bandra Kurla Complex,
Mumbai – 400051.

Sub:- Invoking Para 3 of Drugs (Prices Control) Order, 2013 (DPCO, 2013)
under acute shortage of formulation Viraferonpeg 100 mcg Injection.
– reg.

Sir/Madam,

I am directed to refer on the above mentioned subject and to say that the matter has been examined in the Department of Pharmaceuticals (DoP) in consultation with National Pharmaceutical Pricing Authority (NPPA). In order to maintain normal production, distribution and availability of the formulation Viraferonpeg 100 mcg Injection in the market, it has been decided to invoke the powers of Section 3 (i) of DPCO, 2013.

2. M/s Fulfords (India) Limited is directed:-

(i) to continue to maintain the same level of production and availability as during the period Nov, 2013 to Nov, 2015 of the formulation Viraferonpeg 100 mcg Injection; and



(ii) to submit a weekly report alongwith production plan for the next week to NPPA and to DOP.

3. This order will be valid for 3 (three) months from the date of issue.
4. NPPA will recommend withdrawal or extension as the case may be, two weeks before the expiry of the period.
5. This issues with the approval of Hon'ble Minister (C&F).

Yours faithfully,



(Remya Prabha)
Deputy Director (Pricing)
Phone: 23071162

Copy to:-

1. Chairman, NPPA, YMCA Building, New Delhi, is requested to focus on regular monitoring of Availability/Production of formulation Viraferonpeg 100 mcg Injection in the market and to ensure availability.
2. Drugs Controller General (India), DCGI, FDA Bhawan, ITO, Kotla Road, New Delhi.

1354
5/3/18